Shopping Cart 0
Cart Subtotal
USD 0

AstraZeneca Plc (AZN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. It is also developing new approaches to the treatment of asthma. The company's product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

AstraZeneca Plc (AZN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 13

List of Figures 19

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

AstraZeneca Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deal Details 48

Asset Purchase 48

AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 48

AstraZeneca Acquires Rights to OX-CLI Project from Orexo 50

AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 51

AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 52

Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 53

MedImmune Acquires Patent Rights and Technologies from Allozyne 55

AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 56

AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 58

AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 60

AstraZeneca Acquires Neuroscience Assets From Link Medicine 62

Venture Financing 63

PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 63

Corvidia Therapeutics Raises USD60 Million in Series B Venture Financing 65

Albireo to Raise USD10 Million in Venture Financing 67

G1 Therapeutics Raises USD47 Million in Series C Financing 68

Rani Therapeutics Raises Funds in Financing 70

PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 72

G1 Therapeutics Raises USD33 Million in Series B Financing 74

Moderna Therapeutics Raises USD450 Million in Venture Financing 76

Definiens Raises USD20.3 Million in Venture Financing Round 78

ZS Pharma Raises USD 55 Million In Series D Financing 79

Catabasis Pharma Raises USD 32.4 Million In Series B Financing 81

G1 Therapeutics Raises USD 12.5 Million In Series A Financing 83

Inotek Pharma Raises USD 21 Million In Venture Financing 84

AesRx Raises USD 1.35 Million In Venture Financing 86

Acerta Pharma Raises Funds through Series A Venture Financing 87

Omthera Pharma Raises USD 17.6 Million In Venture Financing 88

Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 89

Pearl Therapeutics Secures USD23.27 Million in Venture Funding 91

Pearl Therapeutics Raises USD 65 Million In Series D Financing 92

Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 94

ZS Pharma Raises USD 46 Million In Series C Financing 96

Definiens Raises USD 13 Million In Venture Financing 98

Coferon Raises USD 12 Million In Series B Venture Financing Round 99

ZS Pharma Secures Additional USD 1 Million In Series A Financing 100

ADC Therapeutics To Raise USD 50 Million In Venture Financing 101

Omthera Pharma Secures Additional USD 5.1 Million In Series B Financing 103

Private Equity 104

ADC Therapeutics Raises USD200 Million in Private Placement of Shares 104

Partnerships 106

MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 106

Biothera Pharma Enters into Partnership with AstraZeneca 107

Voluntis Enters into Collaboration Agreement with AstraZeneca 108

Immunomedics Enters into Partnership with AstraZeneca 109

MedImmune and 4D Molecular Therapeutics Enter into Partnership Agreement 110

Procella Therapeutics and Smartwise Enter into Development Agreement with AstraZeneca 111

Molecular Partners and AstraZeneca Enter into Partnership 112

Avillion Enters into Co-Development Agreement with Pearl Therapeutics 113

Bavarian Nordic Enters into Partnership with Astrazeneca 114

Syndax Pharma Enters into Agreement with AstraZeneca 115

Innate Pharma Expands Agreement with MedImmune 116

X-Chem Enters into Agreement with AstraZeneca 117

AstraZeneca and Imperial College London Enter into Research Partnership 118

G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 119

AstraZeneca Forms Joint Venture with SDIC Fund 120

AstraZeneca Enters into Agreement with University of Michigan 121

AstraZeneca and MedImmune Expands Agreement with Incyte 122

Sawai Pharmaceutical Enters Into Manufacturing And Marketing Agreement with AstraZeneca 123

Roivant Sciences Enters into Development Partnership with AstraZeneca 124

NewLink Genetics Enters into Agreement with AstraZeneca 125

AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 126

BERG Enters into Research Partnership with AstraZeneca 127

Ethris Enters into Research Agreement with Astrazeneca and MedImmune 128

Champions Oncology Enters into Agreement with AstraZeneca 129

AstraZeneca Enters into Agreement with Merck 130

MedImmune Enters into Agreement with Washington University School of Medicine 131

Pieris Pharma Enters into Development Agreement with AstraZeneca 132

Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 133

Genomic Vision Enters into Partnership with AstraZeneca 134

Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 135

Sanofi Enters into Co-Development Agreement with MedImmune 136

APT Therapeutics Enters into Agreement with AstraZeneca 137

AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 138

Bicycle Therapeutics Expands into Agreement with AstraZeneca 139

MedImmune Enters into Co-Development Agreement with Abpro 140

AstraZeneca Enters into Co-Marketing Agreement with Aspen 141

Asthma, AstraZeneca, British Lung Foundation and MRC Technology Enter into Research Agreement 142

Centre for Drug Research and Development Partners with AstraZeneca 143

Foundation Medicine Enters into Agreement with AstraZeneca 144

MedImmune Enters into Agreement with Genisphere 145

Esteve Enters into Agreement with AstraZeneca 146

Foundation Medicine Partners with AstraZeneca 147

Daewoong Pharma Enters into Agreement with AstraZeneca 148

Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 149

Lipigon Pharma Enters into Research Agreement with AstraZeneca 150

PROOF Centre Partners with AstraZeneca 151

AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 152

Allergan Enters into Co-Development Agreement with AstraZeneca 153

Cepheid, MedImmune and Combacte Enter into Agreement 154

Incyte Enters into Agreement with AstraZeneca 155

AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 156

Rani Therapeutics Enters into Agreement with MedImmune 157

AstraZeneca Enters into Agreement with WuXi AppTec 158

AstraZeneca Enters into Agreement with Wallenberg Centre for Protein Research 159

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 160

Igenica Biotherapeutics Enters into Research Agreement with MedImmune 161

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 162

Hutchison MediPharma Enters into Agreement with AstraZeneca 163

Alvogen Enters into Marketing Agreement with AstraZeneca 164

AstraZeneca Enters into Co-Development Agreement with University of Manchestery 165

Peregrine Pharma Expands its Agreement with AstraZeneca 166

Fujifilm Kyowa Kirin Biologics to Form Joint Venture with AstraZeneca 167

MedImmune Enters into Research Agreement with University of Sheffield 168

AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 169

AstraZeneca Enters into Research Agreement with Adelaide Research & Innovation 170

AstraZeneca Enters into Research Agreement with Inserm 171

Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 172

AstraZeneca Forms Joint Venture with Salhi and Hasnaoui 173

Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 174

AstraZeneca Expands Research Agreement with Eli Lilly 175

Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 176

AstraZeneca Enters into Co-Development Agreement with Abbott Labs 177

AstraZeneca Enters into Research Agreement with Sutter Health 178

Celgene Enters into Co-Development Agreement with MedImmune 179

Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 180

MedImmune Enters into Agreement with Juno Therapeutics 181

Bina Technologies Enters into Agreement with AstraZeneca 182

AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 183

PatientsLikeMe Enters into Research Agreement with AstraZeneca 184

AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 185

AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 186

MedImmune Enters into Research Agreement with Joslin Diabetes Center 187

Orca Pharma Enters into Development Agreement with AstraZeneca 188

MedImmune Enters into Research Agreement with University of Manchester 189

MedImmune Enters into Research Agreement with COEBP 190

AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 191

AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 192

AstraZeneca Enters into Research Agreement with Thermo Fisher Scientific 193

AstraZeneca Enters into Research Agreement with Innovative Genomics Initiative 194

Hutchison Sinopharm Pharma Enters into Distribution Agreement with AstraZeneca for Seroquel 195

AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 196

MedImmune Enters into Co-Development Agreement with National Cancer Institute 197

Molplex Enters into Research Collaboration with AstraZeneca 198

Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 199

AstraZeneca Partners with Biognosys 200

Lipigon Pharma Enters into Research Collaboration Agreement with AstraZeneca 201

AstraZeneca Forms Joint Venture with University of Manchester 202

AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 203

Cancer Research UK Forms Joint Venture with MedImmune 205

AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 206

Astrazeneca Enters into Research Agreement with Redx Pharma 207

AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 208

AstraZeneca Enters into Co-Development Agreement with Qiagen 209

AstraZeneca Enters into Co-Development Agreement with Roche 210

Advaxis Enters into Agreement with MedImmune 211

AstraZeneca Enters into Joint Venture Agreement with Max Planck Institute of Molecular Physiology 212

AstraZeneca Extends Collaboration with MRC Technology 213

AstraZeneca Extends its Co-Development Agreement with MRC 214

AstraZeneca Enters into Co-Development Agreement with Academic Drug Discovery Consortium 215

Gustave Roussy Enters into Research Agreement with AstraZeneca 216

AstraZeneca Forms Joint Venture with Samsung Biologics 217

AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 218

AstraZeneca Enters Into Co-Development Agreement With Shenzhen University 220

MedImmune Enters Research Agreement With University of Texas MD Anderson 221

MedImmune Enters Into Research Agreement With Cambridge University 222

Biolojic Design Enters into Partnership with MedImmune 223

AstraZeneca Enters into Research Agreement with Shanghai Institutes for Biological Sciences 224

MedImmune Enters Into Research Agreement With Johns Hopkins University 225

AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 226

AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 227

AstraZeneca Enters Into Research Agreement With Lieber Institute 228

A*STAR Enters Into Co-Development Agreement With AstraZeneca For Antimicrobial Drugs 229

Taris BioMedical Enters Into Research Agreement With AstraZeneca 231

MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 232

AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 233

X-Chem Extends Drug Discovery Agreement With AstraZeneca 234

Labcyte Enters Into Agreement With AstraZeneca To Develop Acoustic Sample Handling Technology 235

AstraZeneca Enters Into Drug Discovery Agreement With Hadasit 236

AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 237

Biosortia Pharma Enters into Research Agreement with AstraZeneca 238

Sarah Cannon Research Institute And AstraZeneca Enter Into Agreement For Personalized Medicine 239

AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 240

MedImmune Enters Into Co-Development Agreement With NGM Biopharma 241

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 243

NeoMed Enters Into Research Agreement With AstraZeneca 245

National Institute on Drug Abuse and AstraZeneca Enter into Partnership 246

Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 247

AstraZeneca Plc - Key Competitors 470

AstraZeneca Plc - Key Employees 471

AstraZeneca Plc - Locations And Subsidiaries 474

Head Office 474

Other Locations & Subsidiaries 474

Joint Venture 480

Recent Developments 481

Strategy And Business Planning 481

Jan 17, 2018: CELLINK establishes R&D lab in AstraZenecas BioVentureHub 481

Oct 01, 2017: Molnlycke to establish R&D innovation unit in AstraZenecas BioVentureHub 482

Apr 25, 2017: AstraZeneca marks a key milestone with the topping out of new global R&D centre and HQ in Cambridge, UK 483

Financial Announcements 485

Jul 26, 2018: AstraZeneca announces H1 2018 results 485

May 18, 2018: AstraZeneca: Q1 2018 Results 499

Feb 02, 2018: AstraZeneca: Full-Year 2017 Results 501

Nov 09, 2017: AstraZeneca Announces Year-To-Date and Q3 2017 Results 503

Jul 27, 2017: AstraZeneca Announce H1 2017 Results 511

Apr 27, 2017: AstraZeneca Announces Q1 2017 Results 521

Feb 02, 2017: Astrazeneca Announces Full-Year and Q4 2016 Results 522

Corporate Communications 523

Sep 06, 2018: AstraZeneca: Directorate change 523

Jun 26, 2018: AstraZeneca Announces Board Committee Changes 524

Apr 05, 2018: AstraZeneca: Non-Executive Directors' Retirement Plans 525

Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 526

Sep 05, 2017: Astrazeneca Appoints Sheri Mccoy and Deborah Disanzo to its Board 527

Aug 16, 2017: Astrazeneca Non-executive Director Retirement 529

Jul 31, 2017: AstraZeneca and MedImmune strengthen immuno-oncology leadership with appointment of two renowned experts31 July 2017 530

Jun 29, 2017: Astra Zeneca: Outcome of the meeting of board of directors held on June 29, 2017 531

May 31, 2017: AstraZeneca appoints Professor Nazneen Rahman to its Board of Directors and Science Committee 532

Mar 06, 2017: Changes to AstraZeneca Board of Directors 533

Jan 27, 2017: AstraZeneca announces availability of saxa / dapa FDC in UK 534

Legal and Regulatory 535

Oct 09, 2018: Astrazeneca sues block Zydus Cadila bid generic nexium 535

Aug 07, 2018: AG Paxton recovers $110 million for Texas in medicaid fraud settlements 536

Aug 01, 2018: AstraZeneca faces US DOJ probe for alleged funding of Iraqi terrorists 537

Jul 26, 2018: US Department of Justice probes Astrazeneca over alleged funding to Iraqi terrorists 538

Government and Public Interest 539

Jul 19, 2018: AstraZeneca to stockpile medicines in preparation for no-deal Brexit 539

Jun 19, 2018: Mechanism controlling multiple sclerosis risk identified 540

Jan 24, 2018: A New Ecosystem Approach to Fight Antibiotic Resistance 541

Jan 11, 2018: New research improves our understanding of cancer cell regulation 543


List Of Figure

List of Figures

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25


List Of Table

List of Tables

AstraZeneca Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

AstraZeneca Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

AstraZeneca Plc, Deals By Therapy Area, 2012 to YTD 2018 23

AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26

AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 48

AstraZeneca Acquires Rights to OX-CLI Project from Orexo 50

AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 51

AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 52

Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 53

MedImmune Acquires Patent Rights and Technologies from Allozyne 55

AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 56

AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 58

AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 60

AstraZeneca Acquires Neuroscience Assets From Link Medicine 62

PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 63

Corvidia Therapeutics Raises USD60 Million in Series B Venture Financing 65

Albireo to Raise USD10 Million in Venture Financing 67

G1 Therapeutics Raises USD47 Million in Series C Financing 68

Rani Therapeutics Raises Funds in Financing 70

PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 72

G1 Therapeutics Raises USD33 Million in Series B Financing 74

Moderna Therapeutics Raises USD450 Million in Venture Financing 76

Definiens Raises USD20.3 Million in Venture Financing Round 78

ZS Pharma Raises USD 55 Million In Series D Financing 79

Catabasis Pharma Raises USD 32.4 Million In Series B Financing 81

G1 Therapeutics Raises USD 12.5 Million In Series A Financing 83

Inotek Pharma Raises USD 21 Million In Venture Financing 84

AesRx Raises USD 1.35 Million In Venture Financing 86

Acerta Pharma Raises Funds through Series A Venture Financing 87

Omthera Pharma Raises USD 17.6 Million In Venture Financing 88

Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 89

Pearl Therapeutics Secures USD23.27 Million in Venture Funding 91

Pearl Therapeutics Raises USD 65 Million In Series D Financing 92

Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 94

ZS Pharma Raises USD 46 Million In Series C Financing 96

Definiens Raises USD 13 Million In Venture Financing 98

Coferon Raises USD 12 Million In Series B Venture Financing Round 99

ZS Pharma Secures Additional USD 1 Million In Series A Financing 100

ADC Therapeutics To Raise USD 50 Million In Venture Financing 101

Omthera Pharma Secures Additional USD 5.1 Million In Series B Financing 103

ADC Therapeutics Raises USD200 Million in Private Placement of Shares 104

MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 106

Biothera Pharma Enters into Partnership with AstraZeneca 107

Voluntis Enters into Collaboration Agreement with AstraZeneca 108

Immunomedics Enters into Partnership with AstraZeneca 109

MedImmune and 4D Molecular Therapeutics Enter into Partnership Agreement 110

Procella Therapeutics and Smartwise Enter into Development Agreement with AstraZeneca 111

Molecular Partners and AstraZeneca Enter into Partnership 112

Avillion Enters into Co-Development Agreement with Pearl Therapeutics 113

Bavarian Nordic Enters into Partnership with Astrazeneca 114

Syndax Pharma Enters into Agreement with AstraZeneca 115

Innate Pharma Expands Agreement with MedImmune 116

X-Chem Enters into Agreement with AstraZeneca 117

AstraZeneca and Imperial College London Enter into Research Partnership 118

G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 119

AstraZeneca Forms Joint Venture with SDIC Fund 120

AstraZeneca Enters into Agreement with University of Michigan 121

AstraZeneca and MedImmune Expands Agreement with Incyte 122

Sawai Pharmaceutical Enters Into Manufacturing And Marketing Agreement with AstraZeneca 123

Roivant Sciences Enters into Development Partnership with AstraZeneca 124

NewLink Genetics Enters into Agreement with AstraZeneca 125

AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 126

BERG Enters into Research Partnership with AstraZeneca 127

Ethris Enters into Research Agreement with Astrazeneca and MedImmune 128

Champions Oncology Enters into Agreement with AstraZeneca 129

AstraZeneca Enters into Agreement with Merck 130

MedImmune Enters into Agreement with Washington University School of Medicine 131

Pieris Pharma Enters into Development Agreement with AstraZeneca 132

Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 133

Genomic Vision Enters into Partnership with AstraZeneca 134

Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 135

Sanofi Enters into Co-Development Agreement with MedImmune 136

APT Therapeutics Enters into Agreement with AstraZeneca 137

AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 138

Bicycle Therapeutics Expands into Agreement with AstraZeneca 139

MedImmune Enters into Co-Development Agreement with Abpro 140

AstraZeneca Enters into Co-Marketing Agreement with Aspen 141

Asthma, AstraZeneca, British Lung Foundation and MRC Technology Enter into Research Agreement 142

Centre for Drug Research and Development Partners with AstraZeneca 143

Foundation Medicine Enters into Agreement with AstraZeneca 144

MedImmune Enters into Agreement with Genisphere 145

Esteve Enters into Agreement with AstraZeneca 146

Foundation Medicine Partners with AstraZeneca 147

Daewoong Pharma Enters into Agreement with AstraZeneca 148

Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 149

Lipigon Pharma Enters into Research Agreement with AstraZeneca 150

PROOF Centre Partners with AstraZeneca 151

AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 152

Allergan Enters into Co-Development Agreement with AstraZeneca 153

Cepheid, MedImmune and Combacte Enter into Agreement 154

Incyte Enters into Agreement with AstraZeneca 155

AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 156

Rani Therapeutics Enters into Agreement with MedImmune 157

AstraZeneca Enters into Agreement with WuXi AppTec 158

AstraZeneca Enters into Agreement with Wallenberg Centre for Protein Research 159

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 160

Igenica Biotherapeutics Enters into Research Agreement with MedImmune 161

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 162

Hutchison MediPharma Enters into Agreement with AstraZeneca 163

Alvogen Enters into Marketing Agreement with AstraZeneca 164

AstraZeneca Enters into Co-Development Agreement with University of Manchestery 165

Peregrine Pharma Expands its Agreement with AstraZeneca 166

Fujifilm Kyowa Kirin Biologics to Form Joint Venture with AstraZeneca 167

MedImmune Enters into Research Agreement with University of Sheffield 168

AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 169

AstraZeneca Enters into Research Agreement with Adelaide Research & Innovation 170

AstraZeneca Enters into Research Agreement with Inserm 171

Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 172

AstraZeneca Forms Joint Venture with Salhi and Hasnaoui 173

Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 174

AstraZeneca Expands Research Agreement with Eli Lilly 175

Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 176

AstraZeneca Enters into Co-Development Agreement with Abbott Labs 177

AstraZeneca Enters into Research Agreement with Sutter Health 178

Celgene Enters into Co-Development Agreement with MedImmune 179

Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 180

MedImmune Enters into Agreement with Juno Therapeutics 181

Bina Technologies Enters into Agreement with AstraZeneca 182

AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 183

PatientsLikeMe Enters into Research Agreement with AstraZeneca 184

AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 185

AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 186

MedImmune Enters into Research Agreement with Joslin Diabetes Center 187

Orca Pharma Enters into Development Agreement with AstraZeneca 188

MedImmune Enters into Research Agreement with University of Manchester 189

MedImmune Enters into Research Agreement with COEBP 190

AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 191

AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 192

AstraZeneca Enters into Research Agreement with Thermo Fisher Scientific 193

AstraZeneca Enters into Research Agreement with Innovative Genomics Initiative 194

Hutchison Sinopharm Pharma Enters into Distribution Agreement with AstraZeneca for Seroquel 195

AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 196

MedImmune Enters into Co-Development Agreement with National Cancer Institute 197

Molplex Enters into Research Collaboration with AstraZeneca 198

Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 199

AstraZeneca Partners with Biognosys 200

Lipigon Pharma Enters into Research Collaboration Agreement with AstraZeneca 201

AstraZeneca Forms Joint Venture with University of Manchester 202

AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 203

Cancer Research UK Forms Joint Venture with MedImmune 205

AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 206

Astrazeneca Enters into Research Agreement with Redx Pharma 207

AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 208

AstraZeneca Enters into Co-Development Agreement with Qiagen 209

AstraZeneca Enters into Co-Development Agreement with Roche 210

Advaxis Enters into Agreement with MedImmune 211

AstraZeneca Enters into Joint Venture Agreement with Max Planck Institute of Molecular Physiology 212

AstraZeneca Extends Collaboration with MRC Technology 213

AstraZeneca Extends its Co-Development Agreement with MRC 214

AstraZeneca Enters into Co-Development Agreement with Academic Drug Discovery Consortium 215

Gustave Roussy Enters into Research Agreement with AstraZeneca 216

AstraZeneca Forms Joint Venture with Samsung Biologics 217

AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 218

AstraZeneca Enters Into Co-Development Agreement With Shenzhen University 220

MedImmune Enters Research Agreement With University of Texas MD Anderson 221

MedImmune Enters Into Research Agreement With Cambridge University 222

Biolojic Design Enters into Partnership with MedImmune 223

AstraZeneca Enters into Research Agreement with Shanghai Institutes for Biological Sciences 224

MedImmune Enters Into Research Agreement With Johns Hopkins University 225

AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 226

AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 227

AstraZeneca Enters Into Research Agreement With Lieber Institute 228

A*STAR Enters Into Co-Development Agreement With AstraZeneca For Antimicrobial Drugs 229

Taris BioMedical Enters Into Research Agreement With AstraZeneca 231

MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 232

AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 233

X-Chem Extends Drug Discovery Agreement With AstraZeneca 234

Labcyte Enters Into Agreement With AstraZeneca To Develop Acoustic Sample Handling Technology 235

AstraZeneca Enters Into Drug Discovery Agreement With Hadasit 236

AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 237

Biosortia Pharma Enters into Research Agreement with AstraZeneca 238

Sarah Cannon Research Institute And AstraZeneca Enter Into Agreement For Personalized Medicine 239

AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 240

MedImmune Enters Into Co-Development Agreement With NGM Biopharma 241

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 243

NeoMed Enters Into Research Agreement With AstraZeneca 245

National Institute on Drug Abuse and AstraZeneca Enter into Partnership 246

Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 247

Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 248

AstraZeneca Enters Into Co-Development Agreement With Moderna Therapeutics For Messenger RNA Therapeutics 249

AstraZeneca Enters Into Co-Development Agreement With Petrov Institute 250

AstraZeneca Enters Into Drug Discovery Agreement With Lead Discovery Center 251

Orexo Enters Into Research Agreement With AstraZeneca For OX-CLI Program 252

Serina Therapeutics Enters into Co-Development Agreement with AstraZeneca 253

Cellular Dynamics International Enters Into Agreement With AstraZeneca On Use Of iPSC-Derived Human Cells In Drug Discovery 254

CytImmune Sciences and AstraZeneca Enter into Research Agreement 255

AstraZeneca Enters into Agreement with LegoChem for Antibiotic-Resistant Bacterial Infections 256

Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 257

AstraZeneca Expands Co-Development Agreement with Isis Pharma 258

Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 259

AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 260

Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 261

AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 262

Charles River Labs Expands its Agreement with AstraZeneca 264

Pharmaron Enters Into Drug Discovery Agreement With AstraZeneca 265

Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 266

AstraZeneca And Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents 268

Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 269

Starpharma Holdings Enters into Agreement with AstraZeneca 270

Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 271

Knode Enters Into Co-Development Agreement With AstraZeneca 273

Assay Depot Enters Into Joint Venture Agreement With AstraZeneca 274

AstraZeneca Enters Into Co-Development Agreement With Cellworks Group 275

AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 276

X-Chem Enters Into Drug Discovery Agreement With AstraZeneca 277

AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 278

AstraZeneca And Conformetrix Enter Into Co-Development Agreement 279

Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 280

Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 281

PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 283

AstraZeneca Rumored To Merge With Amgen 284

Biohaven Therapeutics Enters into Licensing Agreement with AstraZeneca 285

AstraZeneca Enters into Licensing Agreement with Ionis Pharma 286

MedImmune Enters into Licensing Agreement with Compugen 287

Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 288

Kiniksa Pharma Enters into Licensing Agreement with MedImmune 289

AstraZeneca Plc, Key Competitors 470

AstraZeneca Plc, Key Employees 471

AstraZeneca Plc, Subsidiaries 474

AstraZeneca Plc, Joint Venture 480

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

AstraZeneca Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. It is also developing new approaches to the treatment of asthma. The company's product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.

AstraZeneca Plc (AZN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 13

List of Figures 19

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

AstraZeneca Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deal Details 48

Asset Purchase 48

AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 48

AstraZeneca Acquires Rights to OX-CLI Project from Orexo 50

AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 51

AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 52

Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 53

MedImmune Acquires Patent Rights and Technologies from Allozyne 55

AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 56

AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 58

AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 60

AstraZeneca Acquires Neuroscience Assets From Link Medicine 62

Venture Financing 63

PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 63

Corvidia Therapeutics Raises USD60 Million in Series B Venture Financing 65

Albireo to Raise USD10 Million in Venture Financing 67

G1 Therapeutics Raises USD47 Million in Series C Financing 68

Rani Therapeutics Raises Funds in Financing 70

PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 72

G1 Therapeutics Raises USD33 Million in Series B Financing 74

Moderna Therapeutics Raises USD450 Million in Venture Financing 76

Definiens Raises USD20.3 Million in Venture Financing Round 78

ZS Pharma Raises USD 55 Million In Series D Financing 79

Catabasis Pharma Raises USD 32.4 Million In Series B Financing 81

G1 Therapeutics Raises USD 12.5 Million In Series A Financing 83

Inotek Pharma Raises USD 21 Million In Venture Financing 84

AesRx Raises USD 1.35 Million In Venture Financing 86

Acerta Pharma Raises Funds through Series A Venture Financing 87

Omthera Pharma Raises USD 17.6 Million In Venture Financing 88

Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 89

Pearl Therapeutics Secures USD23.27 Million in Venture Funding 91

Pearl Therapeutics Raises USD 65 Million In Series D Financing 92

Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 94

ZS Pharma Raises USD 46 Million In Series C Financing 96

Definiens Raises USD 13 Million In Venture Financing 98

Coferon Raises USD 12 Million In Series B Venture Financing Round 99

ZS Pharma Secures Additional USD 1 Million In Series A Financing 100

ADC Therapeutics To Raise USD 50 Million In Venture Financing 101

Omthera Pharma Secures Additional USD 5.1 Million In Series B Financing 103

Private Equity 104

ADC Therapeutics Raises USD200 Million in Private Placement of Shares 104

Partnerships 106

MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 106

Biothera Pharma Enters into Partnership with AstraZeneca 107

Voluntis Enters into Collaboration Agreement with AstraZeneca 108

Immunomedics Enters into Partnership with AstraZeneca 109

MedImmune and 4D Molecular Therapeutics Enter into Partnership Agreement 110

Procella Therapeutics and Smartwise Enter into Development Agreement with AstraZeneca 111

Molecular Partners and AstraZeneca Enter into Partnership 112

Avillion Enters into Co-Development Agreement with Pearl Therapeutics 113

Bavarian Nordic Enters into Partnership with Astrazeneca 114

Syndax Pharma Enters into Agreement with AstraZeneca 115

Innate Pharma Expands Agreement with MedImmune 116

X-Chem Enters into Agreement with AstraZeneca 117

AstraZeneca and Imperial College London Enter into Research Partnership 118

G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 119

AstraZeneca Forms Joint Venture with SDIC Fund 120

AstraZeneca Enters into Agreement with University of Michigan 121

AstraZeneca and MedImmune Expands Agreement with Incyte 122

Sawai Pharmaceutical Enters Into Manufacturing And Marketing Agreement with AstraZeneca 123

Roivant Sciences Enters into Development Partnership with AstraZeneca 124

NewLink Genetics Enters into Agreement with AstraZeneca 125

AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 126

BERG Enters into Research Partnership with AstraZeneca 127

Ethris Enters into Research Agreement with Astrazeneca and MedImmune 128

Champions Oncology Enters into Agreement with AstraZeneca 129

AstraZeneca Enters into Agreement with Merck 130

MedImmune Enters into Agreement with Washington University School of Medicine 131

Pieris Pharma Enters into Development Agreement with AstraZeneca 132

Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 133

Genomic Vision Enters into Partnership with AstraZeneca 134

Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 135

Sanofi Enters into Co-Development Agreement with MedImmune 136

APT Therapeutics Enters into Agreement with AstraZeneca 137

AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 138

Bicycle Therapeutics Expands into Agreement with AstraZeneca 139

MedImmune Enters into Co-Development Agreement with Abpro 140

AstraZeneca Enters into Co-Marketing Agreement with Aspen 141

Asthma, AstraZeneca, British Lung Foundation and MRC Technology Enter into Research Agreement 142

Centre for Drug Research and Development Partners with AstraZeneca 143

Foundation Medicine Enters into Agreement with AstraZeneca 144

MedImmune Enters into Agreement with Genisphere 145

Esteve Enters into Agreement with AstraZeneca 146

Foundation Medicine Partners with AstraZeneca 147

Daewoong Pharma Enters into Agreement with AstraZeneca 148

Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 149

Lipigon Pharma Enters into Research Agreement with AstraZeneca 150

PROOF Centre Partners with AstraZeneca 151

AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 152

Allergan Enters into Co-Development Agreement with AstraZeneca 153

Cepheid, MedImmune and Combacte Enter into Agreement 154

Incyte Enters into Agreement with AstraZeneca 155

AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 156

Rani Therapeutics Enters into Agreement with MedImmune 157

AstraZeneca Enters into Agreement with WuXi AppTec 158

AstraZeneca Enters into Agreement with Wallenberg Centre for Protein Research 159

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 160

Igenica Biotherapeutics Enters into Research Agreement with MedImmune 161

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 162

Hutchison MediPharma Enters into Agreement with AstraZeneca 163

Alvogen Enters into Marketing Agreement with AstraZeneca 164

AstraZeneca Enters into Co-Development Agreement with University of Manchestery 165

Peregrine Pharma Expands its Agreement with AstraZeneca 166

Fujifilm Kyowa Kirin Biologics to Form Joint Venture with AstraZeneca 167

MedImmune Enters into Research Agreement with University of Sheffield 168

AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 169

AstraZeneca Enters into Research Agreement with Adelaide Research & Innovation 170

AstraZeneca Enters into Research Agreement with Inserm 171

Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 172

AstraZeneca Forms Joint Venture with Salhi and Hasnaoui 173

Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 174

AstraZeneca Expands Research Agreement with Eli Lilly 175

Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 176

AstraZeneca Enters into Co-Development Agreement with Abbott Labs 177

AstraZeneca Enters into Research Agreement with Sutter Health 178

Celgene Enters into Co-Development Agreement with MedImmune 179

Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 180

MedImmune Enters into Agreement with Juno Therapeutics 181

Bina Technologies Enters into Agreement with AstraZeneca 182

AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 183

PatientsLikeMe Enters into Research Agreement with AstraZeneca 184

AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 185

AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 186

MedImmune Enters into Research Agreement with Joslin Diabetes Center 187

Orca Pharma Enters into Development Agreement with AstraZeneca 188

MedImmune Enters into Research Agreement with University of Manchester 189

MedImmune Enters into Research Agreement with COEBP 190

AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 191

AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 192

AstraZeneca Enters into Research Agreement with Thermo Fisher Scientific 193

AstraZeneca Enters into Research Agreement with Innovative Genomics Initiative 194

Hutchison Sinopharm Pharma Enters into Distribution Agreement with AstraZeneca for Seroquel 195

AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 196

MedImmune Enters into Co-Development Agreement with National Cancer Institute 197

Molplex Enters into Research Collaboration with AstraZeneca 198

Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 199

AstraZeneca Partners with Biognosys 200

Lipigon Pharma Enters into Research Collaboration Agreement with AstraZeneca 201

AstraZeneca Forms Joint Venture with University of Manchester 202

AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 203

Cancer Research UK Forms Joint Venture with MedImmune 205

AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 206

Astrazeneca Enters into Research Agreement with Redx Pharma 207

AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 208

AstraZeneca Enters into Co-Development Agreement with Qiagen 209

AstraZeneca Enters into Co-Development Agreement with Roche 210

Advaxis Enters into Agreement with MedImmune 211

AstraZeneca Enters into Joint Venture Agreement with Max Planck Institute of Molecular Physiology 212

AstraZeneca Extends Collaboration with MRC Technology 213

AstraZeneca Extends its Co-Development Agreement with MRC 214

AstraZeneca Enters into Co-Development Agreement with Academic Drug Discovery Consortium 215

Gustave Roussy Enters into Research Agreement with AstraZeneca 216

AstraZeneca Forms Joint Venture with Samsung Biologics 217

AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 218

AstraZeneca Enters Into Co-Development Agreement With Shenzhen University 220

MedImmune Enters Research Agreement With University of Texas MD Anderson 221

MedImmune Enters Into Research Agreement With Cambridge University 222

Biolojic Design Enters into Partnership with MedImmune 223

AstraZeneca Enters into Research Agreement with Shanghai Institutes for Biological Sciences 224

MedImmune Enters Into Research Agreement With Johns Hopkins University 225

AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 226

AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 227

AstraZeneca Enters Into Research Agreement With Lieber Institute 228

A*STAR Enters Into Co-Development Agreement With AstraZeneca For Antimicrobial Drugs 229

Taris BioMedical Enters Into Research Agreement With AstraZeneca 231

MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 232

AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 233

X-Chem Extends Drug Discovery Agreement With AstraZeneca 234

Labcyte Enters Into Agreement With AstraZeneca To Develop Acoustic Sample Handling Technology 235

AstraZeneca Enters Into Drug Discovery Agreement With Hadasit 236

AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 237

Biosortia Pharma Enters into Research Agreement with AstraZeneca 238

Sarah Cannon Research Institute And AstraZeneca Enter Into Agreement For Personalized Medicine 239

AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 240

MedImmune Enters Into Co-Development Agreement With NGM Biopharma 241

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 243

NeoMed Enters Into Research Agreement With AstraZeneca 245

National Institute on Drug Abuse and AstraZeneca Enter into Partnership 246

Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 247

AstraZeneca Plc - Key Competitors 470

AstraZeneca Plc - Key Employees 471

AstraZeneca Plc - Locations And Subsidiaries 474

Head Office 474

Other Locations & Subsidiaries 474

Joint Venture 480

Recent Developments 481

Strategy And Business Planning 481

Jan 17, 2018: CELLINK establishes R&D lab in AstraZenecas BioVentureHub 481

Oct 01, 2017: Molnlycke to establish R&D innovation unit in AstraZenecas BioVentureHub 482

Apr 25, 2017: AstraZeneca marks a key milestone with the topping out of new global R&D centre and HQ in Cambridge, UK 483

Financial Announcements 485

Jul 26, 2018: AstraZeneca announces H1 2018 results 485

May 18, 2018: AstraZeneca: Q1 2018 Results 499

Feb 02, 2018: AstraZeneca: Full-Year 2017 Results 501

Nov 09, 2017: AstraZeneca Announces Year-To-Date and Q3 2017 Results 503

Jul 27, 2017: AstraZeneca Announce H1 2017 Results 511

Apr 27, 2017: AstraZeneca Announces Q1 2017 Results 521

Feb 02, 2017: Astrazeneca Announces Full-Year and Q4 2016 Results 522

Corporate Communications 523

Sep 06, 2018: AstraZeneca: Directorate change 523

Jun 26, 2018: AstraZeneca Announces Board Committee Changes 524

Apr 05, 2018: AstraZeneca: Non-Executive Directors' Retirement Plans 525

Dec 01, 2017: Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer 526

Sep 05, 2017: Astrazeneca Appoints Sheri Mccoy and Deborah Disanzo to its Board 527

Aug 16, 2017: Astrazeneca Non-executive Director Retirement 529

Jul 31, 2017: AstraZeneca and MedImmune strengthen immuno-oncology leadership with appointment of two renowned experts31 July 2017 530

Jun 29, 2017: Astra Zeneca: Outcome of the meeting of board of directors held on June 29, 2017 531

May 31, 2017: AstraZeneca appoints Professor Nazneen Rahman to its Board of Directors and Science Committee 532

Mar 06, 2017: Changes to AstraZeneca Board of Directors 533

Jan 27, 2017: AstraZeneca announces availability of saxa / dapa FDC in UK 534

Legal and Regulatory 535

Oct 09, 2018: Astrazeneca sues block Zydus Cadila bid generic nexium 535

Aug 07, 2018: AG Paxton recovers $110 million for Texas in medicaid fraud settlements 536

Aug 01, 2018: AstraZeneca faces US DOJ probe for alleged funding of Iraqi terrorists 537

Jul 26, 2018: US Department of Justice probes Astrazeneca over alleged funding to Iraqi terrorists 538

Government and Public Interest 539

Jul 19, 2018: AstraZeneca to stockpile medicines in preparation for no-deal Brexit 539

Jun 19, 2018: Mechanism controlling multiple sclerosis risk identified 540

Jan 24, 2018: A New Ecosystem Approach to Fight Antibiotic Resistance 541

Jan 11, 2018: New research improves our understanding of cancer cell regulation 543


List Of Figure

List of Figures

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23

AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25


List Of Table

List of Tables

AstraZeneca Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20

AstraZeneca Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22

AstraZeneca Plc, Deals By Therapy Area, 2012 to YTD 2018 23

AstraZeneca Plc, Medical Devices Deals, 2012 to YTD 2018 25

AstraZeneca Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26

AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 48

AstraZeneca Acquires Rights to OX-CLI Project from Orexo 50

AstraZeneca Acquires US Biologics Manufacturing Facility from Amgen 51

AstraZeneca Acquires Respiratory Drug Business from Actavis in US and Canada 52

Astrazeneca Acquires Almirall Respiratory Franchise for up to USD2.1 billion 53

MedImmune Acquires Patent Rights and Technologies from Allozyne 55

AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 56

AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 58

AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 60

AstraZeneca Acquires Neuroscience Assets From Link Medicine 62

PhaseBio Pharma Raises USD34 Million in Series D Venture Financing 63

Corvidia Therapeutics Raises USD60 Million in Series B Venture Financing 65

Albireo to Raise USD10 Million in Venture Financing 67

G1 Therapeutics Raises USD47 Million in Series C Financing 68

Rani Therapeutics Raises Funds in Financing 70

PhaseBio Pharma Raises USD40 Million in Series C Venture Financing 72

G1 Therapeutics Raises USD33 Million in Series B Financing 74

Moderna Therapeutics Raises USD450 Million in Venture Financing 76

Definiens Raises USD20.3 Million in Venture Financing Round 78

ZS Pharma Raises USD 55 Million In Series D Financing 79

Catabasis Pharma Raises USD 32.4 Million In Series B Financing 81

G1 Therapeutics Raises USD 12.5 Million In Series A Financing 83

Inotek Pharma Raises USD 21 Million In Venture Financing 84

AesRx Raises USD 1.35 Million In Venture Financing 86

Acerta Pharma Raises Funds through Series A Venture Financing 87

Omthera Pharma Raises USD 17.6 Million In Venture Financing 88

Applied Genetic Technologies Raises USD 37.5 Million In Series B Financing 89

Pearl Therapeutics Secures USD23.27 Million in Venture Funding 91

Pearl Therapeutics Raises USD 65 Million In Series D Financing 92

Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 94

ZS Pharma Raises USD 46 Million In Series C Financing 96

Definiens Raises USD 13 Million In Venture Financing 98

Coferon Raises USD 12 Million In Series B Venture Financing Round 99

ZS Pharma Secures Additional USD 1 Million In Series A Financing 100

ADC Therapeutics To Raise USD 50 Million In Venture Financing 101

Omthera Pharma Secures Additional USD 5.1 Million In Series B Financing 103

ADC Therapeutics Raises USD200 Million in Private Placement of Shares 104

MedImmune Enters Into Licensing Agreement With Progenics Pharma For Clostridium Difficile Preclinical Program 106

Biothera Pharma Enters into Partnership with AstraZeneca 107

Voluntis Enters into Collaboration Agreement with AstraZeneca 108

Immunomedics Enters into Partnership with AstraZeneca 109

MedImmune and 4D Molecular Therapeutics Enter into Partnership Agreement 110

Procella Therapeutics and Smartwise Enter into Development Agreement with AstraZeneca 111

Molecular Partners and AstraZeneca Enter into Partnership 112

Avillion Enters into Co-Development Agreement with Pearl Therapeutics 113

Bavarian Nordic Enters into Partnership with Astrazeneca 114

Syndax Pharma Enters into Agreement with AstraZeneca 115

Innate Pharma Expands Agreement with MedImmune 116

X-Chem Enters into Agreement with AstraZeneca 117

AstraZeneca and Imperial College London Enter into Research Partnership 118

G1 Therapeutics Enters into Collaboration Agreement with AstraZeneca 119

AstraZeneca Forms Joint Venture with SDIC Fund 120

AstraZeneca Enters into Agreement with University of Michigan 121

AstraZeneca and MedImmune Expands Agreement with Incyte 122

Sawai Pharmaceutical Enters Into Manufacturing And Marketing Agreement with AstraZeneca 123

Roivant Sciences Enters into Development Partnership with AstraZeneca 124

NewLink Genetics Enters into Agreement with AstraZeneca 125

AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 126

BERG Enters into Research Partnership with AstraZeneca 127

Ethris Enters into Research Agreement with Astrazeneca and MedImmune 128

Champions Oncology Enters into Agreement with AstraZeneca 129

AstraZeneca Enters into Agreement with Merck 130

MedImmune Enters into Agreement with Washington University School of Medicine 131

Pieris Pharma Enters into Development Agreement with AstraZeneca 132

Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 133

Genomic Vision Enters into Partnership with AstraZeneca 134

Kyowa Hakko Kirin Enters into Agreement with AstraZeneca 135

Sanofi Enters into Co-Development Agreement with MedImmune 136

APT Therapeutics Enters into Agreement with AstraZeneca 137

AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 138

Bicycle Therapeutics Expands into Agreement with AstraZeneca 139

MedImmune Enters into Co-Development Agreement with Abpro 140

AstraZeneca Enters into Co-Marketing Agreement with Aspen 141

Asthma, AstraZeneca, British Lung Foundation and MRC Technology Enter into Research Agreement 142

Centre for Drug Research and Development Partners with AstraZeneca 143

Foundation Medicine Enters into Agreement with AstraZeneca 144

MedImmune Enters into Agreement with Genisphere 145

Esteve Enters into Agreement with AstraZeneca 146

Foundation Medicine Partners with AstraZeneca 147

Daewoong Pharma Enters into Agreement with AstraZeneca 148

Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 149

Lipigon Pharma Enters into Research Agreement with AstraZeneca 150

PROOF Centre Partners with AstraZeneca 151

AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 152

Allergan Enters into Co-Development Agreement with AstraZeneca 153

Cepheid, MedImmune and Combacte Enter into Agreement 154

Incyte Enters into Agreement with AstraZeneca 155

AstraZeneca Enters into Co-Development Agreement with Moderna Therapeutics 156

Rani Therapeutics Enters into Agreement with MedImmune 157

AstraZeneca Enters into Agreement with WuXi AppTec 158

AstraZeneca Enters into Agreement with Wallenberg Centre for Protein Research 159

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 160

Igenica Biotherapeutics Enters into Research Agreement with MedImmune 161

MedImmune, GlaxoSmithKline and Vanderbilt University Enter into Agreement 162

Hutchison MediPharma Enters into Agreement with AstraZeneca 163

Alvogen Enters into Marketing Agreement with AstraZeneca 164

AstraZeneca Enters into Co-Development Agreement with University of Manchestery 165

Peregrine Pharma Expands its Agreement with AstraZeneca 166

Fujifilm Kyowa Kirin Biologics to Form Joint Venture with AstraZeneca 167

MedImmune Enters into Research Agreement with University of Sheffield 168

AstraZeneca Enters into Option Agreement with Kyowa Hakko Kirin 169

AstraZeneca Enters into Research Agreement with Adelaide Research & Innovation 170

AstraZeneca Enters into Research Agreement with Inserm 171

Vall d'Hebron Institute of Oncology Enters into Agreement with AstraZeneca 172

AstraZeneca Forms Joint Venture with Salhi and Hasnaoui 173

Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 174

AstraZeneca Expands Research Agreement with Eli Lilly 175

Dr Reddy's Labs Enters into Distribution Agreement with Astrazeneca Pharma 176

AstraZeneca Enters into Co-Development Agreement with Abbott Labs 177

AstraZeneca Enters into Research Agreement with Sutter Health 178

Celgene Enters into Co-Development Agreement with MedImmune 179

Innate Pharma Enters into Co-Development Agreement with AstraZeneca for Immuno-Oncology 180

MedImmune Enters into Agreement with Juno Therapeutics 181

Bina Technologies Enters into Agreement with AstraZeneca 182

AstraZeneca Expands Drug Discovery Agreement with Lead Discovery Center 183

PatientsLikeMe Enters into Research Agreement with AstraZeneca 184

AstraZeneca Enters into Research Agreement with Harvard Stem Cell Institute 185

AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 186

MedImmune Enters into Research Agreement with Joslin Diabetes Center 187

Orca Pharma Enters into Development Agreement with AstraZeneca 188

MedImmune Enters into Research Agreement with University of Manchester 189

MedImmune Enters into Research Agreement with COEBP 190

AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 191

AstraZeneca Enters into Research Agreement with Wellcome Trust Sanger Institute 192

AstraZeneca Enters into Research Agreement with Thermo Fisher Scientific 193

AstraZeneca Enters into Research Agreement with Innovative Genomics Initiative 194

Hutchison Sinopharm Pharma Enters into Distribution Agreement with AstraZeneca for Seroquel 195

AstraZeneca Enters into Research Agreement with University of Texas MD Anderson Cancer Center 196

MedImmune Enters into Co-Development Agreement with National Cancer Institute 197

Molplex Enters into Research Collaboration with AstraZeneca 198

Tetragenetics Enters into Agreement with MedImmune for Drug Discovery Program 199

AstraZeneca Partners with Biognosys 200

Lipigon Pharma Enters into Research Collaboration Agreement with AstraZeneca 201

AstraZeneca Forms Joint Venture with University of Manchester 202

AstraZeneca and MedImmune Enter into R&D Agreement with University of Cambridge 203

Cancer Research UK Forms Joint Venture with MedImmune 205

AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 206

Astrazeneca Enters into Research Agreement with Redx Pharma 207

AstraZeneca Enters into Research Agreement with Mitsubishi Tanabe 208

AstraZeneca Enters into Co-Development Agreement with Qiagen 209

AstraZeneca Enters into Co-Development Agreement with Roche 210

Advaxis Enters into Agreement with MedImmune 211

AstraZeneca Enters into Joint Venture Agreement with Max Planck Institute of Molecular Physiology 212

AstraZeneca Extends Collaboration with MRC Technology 213

AstraZeneca Extends its Co-Development Agreement with MRC 214

AstraZeneca Enters into Co-Development Agreement with Academic Drug Discovery Consortium 215

Gustave Roussy Enters into Research Agreement with AstraZeneca 216

AstraZeneca Forms Joint Venture with Samsung Biologics 217

AstraZeneca Enters Into Drug Discovery Agreement With Medical Research Council 218

AstraZeneca Enters Into Co-Development Agreement With Shenzhen University 220

MedImmune Enters Research Agreement With University of Texas MD Anderson 221

MedImmune Enters Into Research Agreement With Cambridge University 222

Biolojic Design Enters into Partnership with MedImmune 223

AstraZeneca Enters into Research Agreement with Shanghai Institutes for Biological Sciences 224

MedImmune Enters Into Research Agreement With Johns Hopkins University 225

AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 226

AstraZeneca Enters Into Co-Promotion Agreement With Ono Pharma For Dapagliflozin 227

AstraZeneca Enters Into Research Agreement With Lieber Institute 228

A*STAR Enters Into Co-Development Agreement With AstraZeneca For Antimicrobial Drugs 229

Taris BioMedical Enters Into Research Agreement With AstraZeneca 231

MedImmune Enters Into Co-Development Agreement With ADC Therapeutics 232

AstraZeneca Enters Into Co-Promotion Agreement With Janssen For Abiraterone Acetate 233

X-Chem Extends Drug Discovery Agreement With AstraZeneca 234

Labcyte Enters Into Agreement With AstraZeneca To Develop Acoustic Sample Handling Technology 235

AstraZeneca Enters Into Drug Discovery Agreement With Hadasit 236

AstraZeneca Enters Into Co-Development Agreement With FibroGen For FG-4592 237

Biosortia Pharma Enters into Research Agreement with AstraZeneca 238

Sarah Cannon Research Institute And AstraZeneca Enter Into Agreement For Personalized Medicine 239

AstraZeneca, Roche And MedChemica Enter Into Agreement To Accelerate Drug Development 240

MedImmune Enters Into Co-Development Agreement With NGM Biopharma 241

Cancer Research Technology, University of Manchester And AstraZeneca Enters Into Agreement To Develop Cancer Drugs 243

NeoMed Enters Into Research Agreement With AstraZeneca 245

National Institute on Drug Abuse and AstraZeneca Enter into Partnership 246

Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 247

Bind Therapeutics Enters Into Co-Development Agreement With AstraZeneca For Accurin 248

AstraZeneca Enters Into Co-Development Agreement With Moderna Therapeutics For Messenger RNA Therapeutics 249

AstraZeneca Enters Into Co-Development Agreement With Petrov Institute 250

AstraZeneca Enters Into Drug Discovery Agreement With Lead Discovery Center 251

Orexo Enters Into Research Agreement With AstraZeneca For OX-CLI Program 252

Serina Therapeutics Enters into Co-Development Agreement with AstraZeneca 253

Cellular Dynamics International Enters Into Agreement With AstraZeneca On Use Of iPSC-Derived Human Cells In Drug Discovery 254

CytImmune Sciences and AstraZeneca Enter into Research Agreement 255

AstraZeneca Enters into Agreement with LegoChem for Antibiotic-Resistant Bacterial Infections 256

Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 257

AstraZeneca Expands Co-Development Agreement with Isis Pharma 258

Par Pharma Enters Into Distribution Agreement With AstraZeneca For Atacand HCT 259

AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 260

Foundation Medicine Enters Into Agreement With AstraZeneca For Genomic Profiling 261

AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 262

Charles River Labs Expands its Agreement with AstraZeneca 264

Pharmaron Enters Into Drug Discovery Agreement With AstraZeneca 265

Medimmune Enters Into Research Agreement With Cancer Research Institute And Ludwig Institute for Cancer Research 266

AstraZeneca And Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents 268

Medimmune And Wuxi Apptec Form Joint Venture To Develop Biologic MEDI5117 For Chinese Market 269

Starpharma Holdings Enters into Agreement with AstraZeneca 270

Regulus Therapeutics Enters into Collaboration Agreement with AstraZeneca 271

Knode Enters Into Co-Development Agreement With AstraZeneca 273

Assay Depot Enters Into Joint Venture Agreement With AstraZeneca 274

AstraZeneca Enters Into Co-Development Agreement With Cellworks Group 275

AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 276

X-Chem Enters Into Drug Discovery Agreement With AstraZeneca 277

AstraZeneca Aktiebog Enters into Distribution Agreement with Meiji Seika Pharma 278

AstraZeneca And Conformetrix Enter Into Co-Development Agreement 279

Astrazeneca Enters into Agreement with DNDi for Neglected Diseases 280

Amgen Enters into Co-Development Agreement with AstraZeneca for Five Monoclonal Antibodies 281

PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 283

AstraZeneca Rumored To Merge With Amgen 284

Biohaven Therapeutics Enters into Licensing Agreement with AstraZeneca 285

AstraZeneca Enters into Licensing Agreement with Ionis Pharma 286

MedImmune Enters into Licensing Agreement with Compugen 287

Horizon Pharma Enters into Licensing Agreement with MedImmune for MEDI4945 288

Kiniksa Pharma Enters into Licensing Agreement with MedImmune 289

AstraZeneca Plc, Key Competitors 470

AstraZeneca Plc, Key Employees 471

AstraZeneca Plc, Subsidiaries 474

AstraZeneca Plc, Joint Venture 480

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

AstraZeneca Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.